Maria-Antonietta D’Agostino

Apr 26, 2024 | nature.com | Milena L Pachowsky |Markus Eckstein |Stefano Alivernini |Maria-Antonietta D’Agostino |Georg Schett

AbstractBispecific T cell engagers (BiTEs) kill B cells by engaging T cells. BiTEs are highly effective in acute lymphoblastic leukemia. Here we treated six patients with multidrug-resistant rheumatoid arthritis (RA) with the CD19xCD3 BiTE blinatumomab under compassionate use. Low doses of blinatumomab led to B cell depletion and concomitant decrease of T cells, documenting their engager function.